http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2242230-C2

Outgoing Links

Predicate Object
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4523
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-16
filingDate 2001-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2004-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23e69a4844c7d591dcd1dad14d11e049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb8e3ac70823548705f652f89734b909
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ad6b3b193c570d276a382f11c4ccb48
publicationDate 2004-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2242230-C2
titleOfInvention Method for monitoring remote rehabilitation period aftercare after transurethral prostate resection and classic adenectomy in the cases of insufficient satisfaction with operation results
abstract FIELD: medicine. n SUBSTANCE: method involves carrying out complex examination of a patient including the urologic and psychical condition. Psychical disorder severity coefficient is calculated as SC=(A+B+C+D+E+F+G)/7, where A is the IPSS scale L-value, B is Hamilton scale data, C is the HADS scale data, D is the person reaction to the disease, E is the estimated life quality criterion, F is the anamnesis data, G is the psychical disorders expression value. The CS value being less than 1.5, the treatment is carried out according to urologic principles. The value greater than 1.5, the urologic treatment is complemented by administering antidepressants exerting no cholinolythic action. Ipochondrial symptoms and asthenoneurotic syndrome being observed, light neuroleptics and tranquilizers are to be administered. n EFFECT: accelerated treatment course; enhanced effectiveness of treatment.
priorityDate 2001-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419533724
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419526450
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65387
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5574
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID657192
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5452
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8965
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447620017
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415732507
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448506796
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5502
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414864254
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419553097
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5355
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID424953805
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419503067
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419536175
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419492649
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4041
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID1051
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24883432
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3016
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454294023

Total number of triples: 36.